Biological medicinal products such as recombinant proteins, monoclonal antibodies, and many vaccines are produced in cell cultures. Specific detection assays are performed, to make sure that these products are not contaminated with pathogens. Staff members of the Paul-Ehrlich-Institut have taken the lead in developing, on behalf of the WHO, the first internationally recognized reference preparation for tests detecting mycoplasma contamination in cell cultures. The journal “Applied and Environmental Microbiology” reports on this newly developed WHO standard in its online edition of 12 June 2015.
Mycoplasma is a genus of very small bacteria that lack a cell wall. Due to their very small size and their flexible shape, these pathogens are able to pass bacteria filters and, for this reason cannot be safely removed by means of such filters during the manufacture of medicinal products. Mycoplasma include species which cause diseases of the respiratory and urogenital tracts in humans.
Various test methods are applied to ascertain that neither the original cells used for the production of biological medicinal products – the so-called master cell banks – nor the production cells themselves are contaminated with mycoplasma bacteria.
One of the most sensitive test methods is the nucleic acid amplification technique (NAT). It involves amplification of sections of the bacterial genome by a billion, enabling the detection of the pathogenic agent. As with other test methods, a prerequisite for test reliability is its verification using suitable reference materials – so-called WHO International Standards (IS).
Coworkers of PD Dr Micha Nübling, head of the Section Molecular Virology of the Division Virology at the Paul-Ehrlich-Institut, have developed the first IS for NAT testing for mycoplasma (“1st WHO IS for mycoplasma DNA for NAT assay designed for generic mycoplasma detection”).
The Section at the PEI forms part of the WHO Collaborating Centre for Quality Assurance of Blood Products and in vitro Diagnostic Devices at the institute. Part of the development process of the IS involved an international feasibility study, in which four distantly related mycoplasma species were assayed in different concentrations by 21 laboratories using 26 NAT methods.
Based on the results obtained from these studies, the WHO standard was designed and manufactured and finally established by the WHO “Expert Committee on Biological Standardization (ECBS)”. Professor Klaus Cichutek, president of the Paul-Ehrlich-Institut, is a member of the ECBS.
This WHO IS is now available for the determination of quality features of NAT tests (e.g. the detection limit), the calibration of quantitative assays and the definition of regulatory requirements for mycoplasma testing. “We are pleased that we have succeeded in developing this WHO standard, which will contribute to making worldwide test methods for the detection of mycoplasmas - more reliable and comparable with each other“, says PD Dr Micha Nübling.
Nübling CM, Baylis SA, Hanschmann KM, Montag-Lessing T†,
Chudy M, Kreß J, Ulrych U, Czurda S, Rosengarten R, and
the Mycoplasma Collaborative Study Group (2015): World Health Organization International Standard to Harmonize Assays for Detection of Mycoplasma DNA. Appl Environ Microbiol. 2015 Jun 12. pii: AEM.01150-15
The Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines in Langen near Frankfurt/Main, is a senior federal authority reporting to the Federal Ministry of Health (Bundesministerium für Gesundheit, BMG). It is responsible for the research, assessment, and marketing authorisation of biomedicines for human use and veterinary vaccines. Its remit also includes the authorisation of clinical trials and pharmacovigilance, i.e. recording and evaluation of potential adverse effects. Other duties of the institute include official batch control, scientific advice and inspections. In-house experimental research in the field of biomedicines and life science form an indispensable basis for the varied and many tasks performed at the institute. The PEI, with its roughly 800 staff, also has advisory functions at a national level (federal government, federal states (Länder)), and at an international level (World Health Organization, European Medicines Agency, European Commission, Council of Europe etc.).
http://www.ncbi.nlm.nih.gov/pubmed/?term=World+Health+Organization+International... - Abstract
http://aem.asm.org/content/early/2015/06/08/AEM.01150-15.full.pdf - Fulltext Accepted Manuscript
Dr. Susanne Stöcker | idw - Informationsdienst Wissenschaft
Microscope measures muscle weakness
16.11.2018 | Friedrich-Alexander-Universität Erlangen-Nürnberg
Good preparation is half the digestion
16.11.2018 | Max-Planck-Institut für Stoffwechselforschung
Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.
Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...
Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.
Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...
Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.
In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...
On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.
When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure
Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...
09.11.2018 | Event News
06.11.2018 | Event News
23.10.2018 | Event News
16.11.2018 | Health and Medicine
16.11.2018 | Life Sciences
16.11.2018 | Life Sciences